These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19618303)

  • 1. [Intravenous thrombolysis in the treatment of acute ischaemic stroke: 3, 4.5, or 6 hours?].
    Kwieciński H
    Neurol Neurochir Pol; 2009; 43(3):213-5. PubMed ID: 19618303
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis.
    Maiser SJ; Georgiadis AL; Suri MF; Vazquez G; Lakshminarayan K; Qureshi AI
    Int J Stroke; 2011 Feb; 6(1):25-32. PubMed ID: 21205237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and safety of intravenous thrombolysis for acute ischaemic stroke in northern Greece.
    Rudolf J; Tsivgoulis G; Deretzi G; Heliopoulos I; Vadikolias K; Tsiptsios I; Piperidou C
    Int J Stroke; 2011 Feb; 6(1):91-2. PubMed ID: 21205250
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombolysis with alteplase 4.5-6 hours after acute ischemic stroke.
    Zhang B; Sun XJ; Ju CH
    Eur Neurol; 2011; 65(3):170-4. PubMed ID: 21372577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ischaemic stroke: decide rapidly.
    Prescrire Int; 2015 Sep; 24(163):221. PubMed ID: 26417638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we extend thrombolysis indications for acute ischaemic stroke? The IST-3 study.
    Del Medico M; Bonura A;
    Intern Emerg Med; 2013 Apr; 8(3):261-2. PubMed ID: 23456848
    [No Abstract]   [Full Text] [Related]  

  • 7. Questions about authorisation of alteplase for ischaemic stroke.
    Shinton R
    Lancet; 2014 Aug; 384(9944):659-60. PubMed ID: 25152265
    [No Abstract]   [Full Text] [Related]  

  • 8. Should more patients with acute ischaemic stroke receive thrombolytic treatment?
    Wardlaw JM; Sandercock PA; Murray V
    BMJ; 2009 Nov; 339():b4584. PubMed ID: 19906748
    [No Abstract]   [Full Text] [Related]  

  • 9. [Estimation of patient eligibility for thrombolysis in acute ischaemic stroke based on a hospital stroke registry in Warsaw].
    Kobayashi A; Sarzyńska-Długosz I; Niewada M; Skowrońska M; Członkowska A
    Neurol Neurochir Pol; 2006; 40(5):369-75. PubMed ID: 17103349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of good clinical outcome in acute stroke patients treated with intravenous thrombolysis.
    Saňák D; Herzig R; Zapletalová J; Horák D; Král M; Skoloudík D; Bártková A; Veverka T; Heřman M; Kaňovský P
    Acta Neurol Scand; 2011 May; 123(5):339-44. PubMed ID: 20597864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Possible thrombolytic treatment of cerebral ischemia of over 3 hours after the first symptom].
    Cztonkowska A; Kobayashi A
    Neurol Neurochir Pol; 2009; 43(4):400. PubMed ID: 19795553
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcomes of Thai patients with acute ischemic stroke after intravenous thrombolysis.
    Dharmasaroja PA; Dharmasaroja P; Muengtaweepongsa S
    J Neurol Sci; 2011 Jan; 300(1-2):74-7. PubMed ID: 20937509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of tissue plasminogen activator in acute ischemic stroke.
    Hatcher MA; Starr JA
    Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment.
    Diener HC; Foerch C; Riess H; Röther J; Schroth G; Weber R
    Lancet Neurol; 2013 Jul; 12(7):677-88. PubMed ID: 23726849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous thrombolysis for acute ischemic stroke in the 3- to 4·5-hour window--the Malabar experience.
    Salam KA; Ummer K; Pradeep Kumar VG; Noone ML
    Int J Stroke; 2014 Jun; 9(4):426-8. PubMed ID: 23981667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous recombinant tissue plasminogen activator for acute stroke in Poland: an analysis based on the Safe Implementation of Thrombolysis in Stroke (SITS) Registry.
    Kobayashi A; Czlonkowska A; Ahmed N; Romanowicz S; Glonek M; Nyka WM; Opala G; Wahlgren N;
    Acta Neurol Scand; 2010 Oct; 122(4):229-36. PubMed ID: 19919643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal.
    Jones ML; Holmes M
    Health Technol Assess; 2009 Sep; 13 Suppl 2():15-21. PubMed ID: 19804685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).
    Eissa A; Krass I; Bajorek BV
    J Clin Pharm Ther; 2012 Dec; 37(6):620-9. PubMed ID: 22708668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-arterial thrombolysis: tissue plasminogen activator and other thrombolytic agents.
    Samaniego EA; Linfante I; Dabus G
    Tech Vasc Interv Radiol; 2012 Mar; 15(1):41-6. PubMed ID: 22464301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue plasminogen activator use in a patient with acute ischemic stroke coexisting with meningioma.
    Hsieh HC; Chen CH
    Clin Neurol Neurosurg; 2009 Jul; 111(6):562-3. PubMed ID: 19200644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.